• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by ACELYRIN INC.

    3/14/25 9:04:05 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLRN alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001668163
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    ACELYRIN, Inc.
    SEC File Number
    001-41696
    Address of Issuer
    4149 LIBERTY CANYON RD.
    AGOURA HILLS
    CALIFORNIA
    91301
    Phone
    805-456-4393
    Name of Person for Whose Account the Securities are To Be Sold
    Kim Mina
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer
    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    1805249643.0010032556903/17/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common03/15/2025Settlement of vested RSUsIssuerCheckbox not checked4791603/15/2025Equity compensation for services rendered

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units.
    Date of Notice
    03/14/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Eddie Kim, Attorney-in-Fact for Mina Kim

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $SLRN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SLRN

    DatePrice TargetRatingAnalyst
    8/14/2024$18.00 → $6.00Buy → Neutral
    H.C. Wainwright
    7/8/2024$13.00Equal Weight → Overweight
    Wells Fargo
    12/13/2023$11.00Equal Weight
    Wells Fargo
    12/8/2023$8.00Neutral
    Citigroup
    9/13/2023$19.00Overweight → Equal-Weight
    Morgan Stanley
    9/5/2023$44.00Buy
    H.C. Wainwright
    5/30/2023Overweight
    Morgan Stanley
    5/30/2023$31.00Buy
    Jefferies
    More analyst ratings

    $SLRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ayurmaya Capital Management Company, Lp returned 9,334,735 shares to the company (SEC Form 4)

    4 - ACELYRIN, Inc. (0001962918) (Issuer)

    5/23/25 4:23:20 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Kim Mina was granted 89,526 shares and returned 770,833 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - ACELYRIN, Inc. (0001962918) (Issuer)

    5/23/25 4:11:54 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Cozadd Bruce C

    4 - ACELYRIN, Inc. (0001962918) (Issuer)

    5/23/25 4:11:07 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLRN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by ACELYRIN INC.

    SCHEDULE 13D/A - ACELYRIN, Inc. (0001962918) (Subject)

    5/23/25 4:15:26 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by ACELYRIN INC.

    SCHEDULE 13D/A - ACELYRIN, Inc. (0001962918) (Subject)

    5/23/25 4:01:03 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by ACELYRIN INC.

    EFFECT - ACELYRIN, Inc. (0001962918) (Filer)

    5/23/25 12:15:04 AM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLRN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alumis Stockholders Approve Merger with ACELYRIN

    SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with ACELYRIN, INC. (NASDAQ:SLRN) at its Special Meeting of Stockholders. Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, "We thank our stockholders for their support for the merger and with this milestone now complete, we are moving expeditious

    5/13/25 1:00:00 PM ET
    $ALMS
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

    LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that at the Company's special meeting of stockholders held earlier today, its stockholders voted to approve the adoption of the Company's merger agreement with Alumis Inc. (NASDAQ:ALMS). As previously announced, under the terms of the amended merger agreement, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned at the closing of the transaction. "We appreciate our stockholders' support for our merger

    5/13/25 1:00:00 PM ET
    $ALMS
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote "FOR" the Proposed Transaction with Alumis

    ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today LOS ANGELES, May 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that leading independent proxy advisory firm Institutional Shareholder Services ("ISS") has recommended that ACELYRIN stockholders vote "FOR" the proposed merger ("Proposed Transaction") of the Company with Alumis Inc. (NASDAQ:ALMS). The Company's special meeting of stockholders to vote on the Proposed Transaction is scheduled for May 13, 2025. ACELYRIN urges its stockholders to vote FOR the Pr

    5/6/25 4:30:00 PM ET
    $ALMS
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ACELYRIN downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded ACELYRIN from Buy to Neutral and set a new price target of $6.00 from $18.00 previously

    8/14/24 7:48:43 AM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ACELYRIN upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded ACELYRIN from Equal Weight to Overweight and set a new price target of $13.00

    7/8/24 8:17:02 AM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on ACELYRIN with a new price target

    Wells Fargo initiated coverage of ACELYRIN with a rating of Equal Weight and set a new price target of $11.00

    12/13/23 8:08:18 AM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLRN
    Leadership Updates

    Live Leadership Updates

    View All

    Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

    Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027 Webcast to be held tomorrow, March 28, 2024 at 8:30 a.m. E.T. WAYNE, Pa. and ROCKVILLE, Md., March 27, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced it has acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio, Inc. Concurrent with the acquisition, Ava

    3/27/24 4:01:00 PM ET
    $AVTX
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications

    Highly accomplished leader bringing more than 25 years of investor relations, communications, and operational & strategic finance experience at public healthcare companies LOS ANGELES, Feb. 15, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications. Reporting to Founder and CEO Shao-Lee Lin, MD, PhD, Ms. Lee will be responsible for leading investor relations and corporate communications and will join the company's Senior Leadership Team.

    2/15/24 4:05:00 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors

    LOS ANGELES, Dec. 20, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Lynn Tetrault to its board of directors. "I am pleased to welcome Lynn to our board of directors as we close our first year as a publicly traded company. Lynn is a highly accomplished biopharma executive and her extensive expertise spanning global human capital strategy, talent management, business operations, and corporate affairs adds a valuable dimension to support our evolving company," said Shao-Lee Lin, MD, PhD, Founder and CEO of ACELYRIN

    12/20/23 4:30:00 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLRN
    Financials

    Live finance-specific insights

    View All

    ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

    LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response to Tang Capital Partners' continued rapid accumulation of 8.8% of ACELYRIN'S outstanding common stock, its Board of Directors has approved the adoption of a limited-duration stockholder rights plan ("Rights Plan"). The ACELYRIN Board and management team continue to engage with stockholders and are focused on maximizing stockholder value. Pursuant to the Rights Plan, the Company is issuing one right for each share of common stock as of the close

    3/13/25 7:00:00 AM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

    Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN's lonigutamab to confirm differentiation in a capital efficient manner Pro forma cash position of approximately $737 million as of December 31, 2024, provides runway into 2027, beyond expected multiple clinical readouts for highly differentiated late-stage portfolio Alumis and ACELYRIN stockholders to own ~55% and ~45%, respectively, of combined company on a fully diluted basis Combined company wi

    2/6/25 4:15:00 PM ET
    $ALMS
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease

    Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile Conducted positive end of Phase 2 FDA meeting; Phase 3 program expected to be initiated in Q1 2025 Topline Phase 3 data expected in second half of 2026; cash runway expected through mid-2027 Conference call to review unmet need in TED, new Phase 2 data and Phase 3 program design to be held today, January 6, 2025, at 4:30 PM ET LOS ANGELES, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery

    1/6/25 4:00:00 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SLRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ACELYRIN INC.

    SC 13G/A - ACELYRIN, Inc. (0001962918) (Subject)

    11/14/24 1:28:35 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by ACELYRIN INC.

    SC 13G/A - ACELYRIN, Inc. (0001962918) (Subject)

    11/12/24 12:13:00 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by ACELYRIN INC.

    SC 13G - ACELYRIN, Inc. (0001962918) (Subject)

    11/4/24 10:56:23 AM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care